About

Dr. Santhosh Palani has served on Acrivon's Board since March 2024 and chairs its Nominating & Corporate Governance Committee. He has been founder and CEO of the investment advisory firm PSP Research since November 2024 and was an investment partner at PFM Health Sciences from 2020 to 2024, leading public and private biotechnology investments. Earlier he was a principal at New Enterprise Associates. He currently serves on the board of Pyxis Oncology. Dr. Palani holds a Ph.D. in bioengineering from the University of Pennsylvania, an M.S. in chemical engineering from Texas A&M University and a B.S. in chemical engineering from the University of Madras, and is a CFA charterholder. He serves on Acrivon's Compensation Committee.

Roles

Acrivon Therapeutics, Inc.
Director · Current role
March 2024–present
PSP Research
Founder & Chief Executive Officer
2024 - present
PFM Health Sciences
Investment Partner
2020 - 2024
New Enterprise Associates (NEA)
Principal
—

External Roles

Pyxis Oncology
Director
—

Director Compensation

FY 2025
Fees earned or paid in cash
$57,500
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$17,870
ComponentStock options granted during 2025, ASC 718 grant-date fair value
All other compensation
$42,938
ComponentConsulting fees under a business-development advisory agreement
Total
$118,308

Also at Acrivon Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.